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diabetes mellitus type 2 on different therapeutic
regimens: a one-year prospective study
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Majed S Alokail2,3,4, Yousef Al-Saleh4,7, Sudhesh Kumar8 and George P Chrousos3,9Abstract
Background: Little or no research has determined the effect of vitamin D3 supplementation in conjunction with
pharmacological and non-pharmacological approaches in the diabetes mellitus type 2 (DMT2) patients. The
objective of this study was to determine the effect of vitamin D3 supplementation in a cohort of Saudi DMT2
population on diet, insulin and/or different oral hypoglycemic agents and compare them with a non-DMT2 control
cohort.
Methods: A total of 499 randomly selected Saudi subjects divided into 8 groups [Non-DMT2 Control = 151;
Rosiglitazone alone = 49; Diet = 15; Insulin alone = 55; Insulin + Orals = 12; Metformin alone = 121; Oral agents
combination = 37; Sulphonylurea alone = 59] were included in this 12-month interventional study. All DMT2 patients
were given 2000 IU vitamin D3 daily, while the control group received none but were advised to increase sun
exposure. Anthropometrics, glucose, lipid profile and 25-hydroxyvitamin D (25-OHVitD) were measured at baseline,
6 and 12 months.
Results: Circulating 25-OHVitD concentrations improved in all patient groups. The metformin group showed the
highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to
baseline (p < 0.001). No significant changes were observed in the BMI and glucose in any of the DMT2 groups. In
contrast, the insulin + oral agents group showed more significant improvements in the metabolic profile, which
included triglycerides and total cholesterol, as well as systolic blood pressure and HDL-cholesterol in males. Also,
significant decreases in triglycerides were observed in the rosiglitazone and insulin + oral hypoglycemic agent
groups both at 6 and 12 months of supplementation (both p-values <0.001).
Conclusion: While in all DMT2 groups circulating levels of 25-OHVitD increased after supplementation, in DMT2
patients on insulin in combination with other drugs benefitted the most in improving cardiovascular risk.
Metformin improves 25-hydroxyvitamin D levels but did not seem to confer other added cardiometabolic benefits.
Keywords: Vitamin D, Vitamin D supplementation, Diabetes mellitus, Anti-diabetes therapies* Correspondence: alkharfy@ksu.edu.sa
1Department of Clinical Pharmacy, College of Pharmacy, King Saud
University, PO Box 2457, 11451, Riyadh, Saudi Arabia
3Biomarkers Research Program, King Saud University, 11451, Riyadh, Saudi
Arabia
Full list of author information is available at the end of the article
© 2013 Alkharfy et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Alkharfy et al. Cardiovascular Diabetology 2013, 12:113 Page 2 of 10
http://www.cardiab.com/content/12/1/113Background
Vitamin D deficiency has been a global pandemic for a
while [1,2], yet the level of attention given by the scien-
tific and clinical community was only recently stimu-
lated, primarily because of the pleiotropic effects of this
hormone outside the skeletal system. Vitamin D defi-
ciency has been consistently associated with hyperten-
sion, diabetes mellitus, cardiovascular disease, stroke,
multiple sclerosis, inflammatory bowel disease, osteopor-
osis, periodontal disease, macular degeneration, mental
illness, propensity to fall, chronic pain and various can-
cers [3]. In the Kingdom of Saudi Arabia (KSA), as well
as neighboring countries in the Middle East and North
Africa, where there is a recent surge in the incidence of
osteoporosis, major risk factors included evidence that
points to an overwhelming prevalence of vitamin D defi-
ciency [4].
Several interventional studies have been conducted in
response to the dilemma mentioned above. We previ-
ously observed modest benefits conferred by vitamin D
correction in deficient populations through non-
pharmacologic means among adults [5,6]. We also docu-
mented the benefits of vitamin D supplementation
among patients with diabetes mellitus type 2 (DMT2)
[7], another chronic non-communicable disease highly
prevalent in KSA [8]. In all previous studies mentioned,
the favorable effects of improved vitamin D status are
most evident in the lipid profile of subjects, reaffirming
the hypothesis that vitamin D deficiency contributes to
the pathogenesis of atherogenic dyslipidemia [9].
Little or no research has determined the effect of vita-
min D3 supplementation when given in conjunction
with existing non-pharmacological and pharmacological
approaches to the DMT2 population. Hence, this study
primarily determined the effect of vitamin D3 supple-
mentation in a cohort of Saudi DMT2 population on
different therapeutic regimens and compared them with
a non-DMT2, non-vitamin D supplemented control
cohort.
Methods
Site and duration of the study
This is a multi-center, interventional study conducted at
5 primary health care out-patient clinics (Al-Fawaz, Al-
Nasim, Al-Marwah, Al-Badia and Gubeirah) and one
tertiary hospital (King Abdulaziz University Hospital) in
the central region of Riyadh, KSA. Ethics approval was
obtained from the Ethics Committee of the College of
Medicine Research Center at King Saud University,
Riyadh, KSA.
Subjects
A total of 760 adult Saudi patients with or without
DMT2 were initially recruited to take part in thisinterventional study. These subjects were recruited as
part of the on-going Biomarker Screening Project of
King Saud University in collaboration with the Ministry
of Health which began in 2008. In brief, this project is
connected with the different primary health care centers
in Riyadh and aims to recruit randomly selected Saudis
aged 1–85 for population and epidemiological studies on
a nationwide scale. Out of the 760 subjects, 261 dropped
out for various reasons (non-compliance, change of
medication, lost to follow up, etc.). The final count, 348
adult Saudi patients (195 males and 153 females) with
controlled DMT2 aged 21 years and above but not ex-
ceeding 60 years of age, and another 151 matched non-
diabetic Saudi adults (72 males and 79 females) were the
only subjects who were able to finish the intervention
study. Exclusion criteria were the following: Patients tak-
ing mineral oil products, using antacids regularly, taking
cortisone or other steroids, under diuretics, taking
weight-loss drugs, under phenobarbital and phenytoin
medications, having liver problems, gallbladder disease
or gastrointestinal disorders and taking daily multivita-
mins including calcium. Calcium metabolism abnormal-
ities such as evidence of metabolic disease (Paget’s
disease or osteomalacia), hyperparathyroidism, renal
stone disease, and abnormal levels of calcium, phosphor-
ous and alkaline phosphatase were also excluded.
Subjects were divided into 8 groups based on their
existing diabetic therapy: (A) Non-DMT2 Control (B)
Rosiglitazone (C) Diet (D) Insulin (E) Insulin + Orals (F)
Metformin (G) Oral agents-combination (those who are
not on monotherapy aside from insulin + orals) and (H)
Sulphonylureas. Each DMT2 group was given vitamin D
supplements (2000 IU) in tablet form (Vigantoletten;
Merck Pharma, Germany) daily for 12 months during
which all laboratory parameters were repeated. The non-
DMT2 control group were not given vitamin D supple-
ments but instead were given advise to increase sun
exposure (minimum body parts exposed should include
face, neck, hands and arms, or at least 26% of the body
surface area) and daylight outdoor activity during the
entire study. All subjects were provided with a general
questionnaire which includes thorough past and present
medical history and detailed medication information.
Subjects were required to submit written informed con-
sents prior to being included in the study. None of the
subjects included in the analysis changed their medica-
tion regimen during the entire study period.
Anthropometrics
All anthropometric parameters were measured while the
subject was standing erect and barefoot. The hips were
measured using a standardized non-stretchable fiber
measuring tape. It was then taken as the greatest cir-
cumference at the level of greater trochanters (the
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was measured as the smallest horizontal girth between
the costal margins and the iliac crests at minimal respir-
ation. Waist-hip ratio was calculated using the formula
waist (cm) divided by hips (cm). Height and weight were
determined using standardized conventional methods.
Body mass index was calculated using the formula:
weight in kilograms (kg) divided by height in squared
meters (m2). A standardized mercury sphygmomanom-
eter was used to take the blood pressure of each partici-
pant 30 minutes after complete rest.
Laboratory parameters
Subjects were required to submit overnight fasting blood
samples utilized for the different metabolic parameters.
Fasting blood glucose and lipid profile were determined
using routine laboratory procedures (Konelab, Finland).
25-hydroxyvitamin D (25-OHVitD) level was measured
using an enzyme-linked immunosorbent assay (ELISA)
(IDS Ltd., Boldon Colliery, Tyne & Wear, UK). The
inter- and intra-assay variabilities were 5.3% and 4.6%.
All measurements were done in a DEQAS- (Vitamin D
External Quality Assessment Scheme) participating la-
boratory, the Biomarkers Research Program (BRP) of
King Saud University, Riyadh, KSA.
Statistical analysis
All statistical analyses were done using SAS (Statistical
Analysis System) software version 9.1.3; (SAS institute,
Cary, NC, USA). Non–Gaussian variables were logarith-
mically transformed. Data was quantified by least square
means and corresponding standard error. To compare
differences between treatment groups in outcomes over
time, General Linear models (PROC GLM procedure)
was used. Statistically significant follow up differences or
effects from baseline were determined using Bonferroni
multiple comparison test. Level of significance was set at
p ≤ 0.05.
Results
Vitamin D
With the exception of the diet and oral agents-combination
group, all other groups showed a significant increase in
serum 25-OHVitD levels as compared with mean baseline
status (Table 1). Furthermore, this improvement in 25-
OHVitD status was most pronounced after 6 months sup-
plementation, with the 12-month follow-up slightly lower
than the 6-month follow-up, but still significantly higher
than baseline. This observation remained consistent even
after stratifying the groups according to gender. The
rosiglitazone and diet groups in females failed to achieve
significance possibly because of the small sample size
(Table 2). A comparison of 25-OHVitD levels betweencontrol and DMT2 groups showed higher baseline 25-
OHVitD in males (both control and DMT2) than females
(Figure 1).BMI
The mean BMI of the control group fell within the over-
weight category, while the mean BMI of the entire DM
group fell within the obese-range. No significant change
in mean BMI was observed across the follow-ups and
this observation even after stratification for gender.Blood pressure
There was no significant change in the mean systolic pres-
sure from baseline in any of the groups up to 12 months
(Table 1). However, a significant increase was noted in the
mean diastolic pressure of the Rosiglitazone group as
compared with baseline, while the rest of the groups were
similar. After stratifying the groups by gender, we ob-
served a significant decrease from baseline compared with
12-month follow-up in the mean systolic blood pressure
among males in the insulin + oral group, as well as males
and females in the oral agent-combinations group.
Furthermore, there was a significant increase in the mean
diastolic blood pressure from baseline compared to the
12-month follow-up among males in the rosiglitazone, in-
sulin + oral and oral agent-combinations groups. This
observation was not observed in females, whose mean dia-
stolic blood pressure remained stable along follow-ups.Lipid profile
In all groups, there was no significant change noted
in the mean cholesterol levels. However, significant
improvements were observed in the Rosiglitazone and
insulin + orals group in terms of decreased levels of
triglycerides, which were not apparent in other
groups. Consequently, there was a significant increase
in the mean HDL-cholesterol levels in the control
group, but not apparent in all DMT2 groups. Strati-
fied by gender, significant improvements were noted
in the insulin + orals group in both males and fe-
males, as well as the females in the insulin group, in
terms of decreased mean total cholesterol. Decreased
levels of mean triglycerides were noted in the male
subjects under rosiglitazone, insulin + orals and oral
agent-combinations, as well as the females in the in-
sulin + orals group. With regards to HDL-cholesterol
levels, both males and females in the control group,
as well as the males in the insulin + orals group had
a significant increase from baseline all the way to the
12-month follow-up (Table 3). The rest of the com-
parisons were non-significant.
Table 1 Group comparisons of metabolic parameters at different time points
Control Rosiglitazone Diet Insulin Insulin + Orals Metformin Oral agents combination Sulphonylurea
N 151 49 15 55 12 121 37 59
Gender (M/F) 72/79 48/1 4/11 30/25 6/6 65/56 16/21 26/33
Obesity (%) 41.3 51.1 66.7 73.8 66.7 57.3 79.4 48.9
Hypertension (%) 21.9 38.8 26.7 29.1 29.1 32.2 25.0 27.1
Dyslipidemia (%) 0.7 16.3 6.7 14.5 8.3 12.4 2.7 10.2
25-Hydroxyvitamin D (nmol/l)
Baseline 19.4 ± 1.0 33.3 ± 1.0 24.4 ± 1.1 32.2 ± 1.0 34.1 ± 1.1 34.8 ± 1.0 34.6 ± 1.1 38.3 ± 1.0
6 months 27.4 ± 1.0* 47.8 ± 1.1* 34.3 ± 1.2 55.7 ± 1.1* 55.8 ± 1.1* 62.4 ± 1.1* 46.0 ± 1.1 51.2 ± 1.1*
12 months 25.8 ± 1.1* 49.9 ± 1.2* 26.7 ± 1.3 46.1 ± 1.1* 48.1 ± 1.2* 55.3 ± 1.1* 46.8 ± 1.1 46.8 ± 1.1*
% Change at 6 months C 34.3 (12.0, 56.6)a 36 (10.2, 61.8)b 34.1 (−9.3, 72.3) 54.3 (25.0, 83.7)b 49.1 (−3.2, 68.3) 62.6 (39.1, 86.1) a 28.5 (−7.3, 64.4) 28.8 (2.2, 55.4)b
% Change at 12 months C 28.6 (6.0, 51.4) a 40 (3.2, 77.3)a 9.2 (−12.8,65.3) 35.6 (3.2, 68.0)a 34.3 (−2.1, 69.7) 50.6 (23.4, 77.9) a 30.2 (−14.0,74.4) 19.8 (−13.2, 52.9)a
P-value (groups) < 0.001; P-value (time) < 0.001; P-Value (interaction) = 0.04
Systolic BP (mmHg)
Baseline 115.6 ± 1.1 129.0 ± 1.0 124.2 ± 1.0 126.5 ± 1.0 129.1 ± 1.0 126.1 ± 1.0 134.1 ± 1.1 126.5 ± 1.0
6 months 113.3 ± 1.1 130.0 ± 1.0 124.3 ± 1.0 123.5 ± 1.0 132.5 ± 1.0 124.8 ± 1.0 131.1 ± 1.0 129.7 ± 1.0
12 months 115.4 ± 1.1 130.9 ± 1.0 130.0 ± 1.1 128.1 ± 1.0 130.5 ± 1.0 127.4 ± 1.1 127.7 ± 1.0 127.9 ± 1.0
% Change at 6 months C −2.4 (−8.8, 3.8) 1.4 (−5.8, 8.7) 0.0 −2.4 (−10.4, 5.5) 2.1 (−12.2, 16.6) −1.0 (−6.3,4.3) −2.2 (−11.6, 7.1) 2.5 (−4.9, 9.9)
% Change at 12 months C 0.2 (−7.0, 6.7) 0.9 (−8.1, 10.0) 4.7 (−24.8, 34.2) 1.1 (−8.8, 11.1) 0.6 (−16.0, 17.3) 1.0 (−5.2, 7.4) −4.8 (−16.5, 6.7) 1.1 (−7.8, 10.0)
P-value (groups) < 0.001; P-value (time) = 0.51; P-Value (interaction) = 0.71
Diastolic BP (mmHg)
Baseline 74.5 ± 1.0 71.5 ± 1.0 77.4 ± 1.2 78.2 ± 1.0 75.6 ± 1.0 80.5 ± 1.2 77.5 ± 1.0 79.8 ± 1.1
6 months 72.9 ± 1.0 81.2 ± 1.0* 73.0 ± 1.1 76.7 ± 1.0 79.8 ± 1.1 78.1 ± 1.1 82.3 ± 1.1 77.8 ± 1.0
12 months 73.5 ± 1.0 84.3 ± 1.1* 73.0 ± 1.1 78.2 ± 1.0 80.4 ± 1.2 79.5 ± 1.1 79.5 ± 1.1 81.3 ± 1.1
% Change at 6 months C −1.9 (−11.0, 7.2) 11.9 (1.3, 22.5) −6.8 (−32.1, 18.4) −1.7 (−13.3, 9.8) 5.4 (−15.5, 26.4) −3.1 (−10.8, 4.7) 5.7 (−7.8, 19.2) −2.5 (−13.4, 8.2)
% Change at 12 months C −1.2 (−11.5, 8.9) 15.5 (2.2, 28.2) −6.8 (−49.0, 36.1) 0.0 6.2 (−17.9, 30.4) −1.3 (−10.5, 7.8) 2.2 (−14.6,19.1) 1.8 (−11.2, 14.8)
P-value (groups) < 0.001; P-value (time) = 0.54; P-Value (interaction) = 0.002
BMI (kg/m2)
Baseline 28.5 ± 1.1 30.1 ± 1.1 30.1 ± 1.2 33.4 ± 1.2 31.5 ± 1.0 32.4 ± 1.1 32.9 ± 1.0 32.3 ± 1.0
6 months 28.5 ± 1.1 30.1 ± 1.2 31.1 ± 1.2 35.0 ± 1.2 31.4 ± 1.0 28.2 ± 1.0 30.5 ± 1.0 32.2 ± 1.1
12 months 28.5 ± 1.1 30.1 ± 1.2 - 35.1 ± 1.3 31.6 ± 1.0 30.0 ± 1.1 32.2 ± 1.1 30.6 ± 1.2
% Change at 6 months C 0 0 0 0 0 0 0 0
% Change at 12 months C 0 0 0 0 0 0 0 0
P-value (groups) < 0.001; P-value (time) = 0.18; P-Value (interaction) = 0.36
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Table 1 Group comparisons of metabolic parameters at different time points (Continued)
Total Cholesterol (mmol/l)
Baseline 4.7 ± 1.0 4.8 ± 1.0 5.3 ± 1.0 5.1 ± 1.0 5.4 ± 1.0 5.3 ± 1.0 4.9 ± 1.0 5.2 ± 1.0
6 months 4.4 ± 1.0 4.4 ± 1.0 5.4 ± 1.1 4.9 ± 1.1 5.1 ± 1.1 5.2 ± 1.0 4.8 ± 1.0 5.1 ± 1.0
12 months 4.1 ± 1.0 4.1 ± 1.0 5.8 ± 1.2 4.6 ± 1.0 4.4 ± 1.2 4.9 ± 1.0 4.5 ± 1.0 5.1 ± 1.0
% Change at 6 months C −7.0 (−24.8,10.7) −7.8 (−20.5, 4.7) 2.3 (−28.0, 32.7) −2.0 (−16.1, 12.1) −5.6 (−31.1, 19.9) −0.7 (−10.1, 8.7) −2.2 (−18.9,14.4) −1.2 (−13.9, 11.3)
% Change at 12 months C −2.9 (−7.5, 13.5) −14.8 (−32.6, 2.9) 10.1 (−29.9, 50.3) −9.7 (−24.0, 5.4) −19.5 (−52.5, 13.4) −6.5 (−17.5, 4.4) −9.3 (−29.6, 11.0) −1.6 (−17.8, 14.5)
P-value (groups) < 0.001; P-value (time) = 0.01; P-Value (interaction) = 0.17
Triglycerides (mmol/l)
Baseline 1.2 ± 0.02 2.4 ± 0.04 1.6 ± 0.07 1.8 ± 0.04 2.5 ± 0.08 1.9 ± 0.03 2.0 ± 0.05 2.0 ± 0.04
6 months 1.2 ± 0.04 1.6 ± 0.04* 1.4 ± 0.13 1.8 ± 0.05 1.9 ± 0.09* 2.1 ± 0.04 1.7 ± 0.06 2.0 ± 0.04
12 months 1.2 ± 0.04 1.5 ± 0.07* 1.7 ± 0.18 1.5 ± 0.06 1.9 ± 0.14 2.0 ± 0.04 1.6 ± 0.09 2.0 ± 0.05
% Change at 6 months C 0 - 42.5 a (−18.1,-66.8) −13.1 (−71.2, 45.2) 0 −29.4 a (−78.7, 19.8) 8.4 (−9.6, 26.6) −15.0 (47.1, 17.0) 0
% Change at 12 months C 0 −39.2 a (−5.0, -73.2) 4.0 (−72.3, 82.0) −9.2 (−65.0, 83.6) −28.3 a (−91.0, 35.0) 2.7 (−18.3, 23.8) −23.4 (−62.4, 15.7) 0
P-value (groups) < 0.001; P-value (time) = 0.02; P-Value (interaction) < 0.001
HDL-Cholesterol (mmol/l)
Baseline 0.66 ± 0.03 0.95 ± 0.06 1.0 ± 0.09 1.0 ± 0.05 0.91 ± 0.10 0.93 ± 0.03 1.0 ± 0.06 0.94 ± 0.04
6 months 1.0 ± 0.06* 1.0 ± 0.14 0.93 ± 0.28 1.1 ± 0.11 0.90 ± 0.23 0.89 ± 0.07 1.1 ± 0.15 1.0 ± 0.10
12 months 0.98 ± 0.08* 0.98 ± 0.10 - 0.81 ± 0.10 1.0 ± 0.35 0.93 ± 0.09 0.99 ± 0.14 1.0 ± 0.12
% Change at 6 months C 42.7 a (16.6, 68.9) 8.3 (−49.0,65.8) −11.3 (−32.6,26.7) 1.3 (−.45.4, 48.4) 1.3 (−63.2, 56.7) −3.5 (−33.1, 26.0) 11.7 (−51.0, 74.0) 6.4 (−32.6, 45.2)
% Change at 12 months C 37.3 a (4.3, 70.3) 3.2 (−42.4,48.9) - −26.1 (−70.1, 18.6) 12.2 (−14.8, 26.3) 0.0 1.5 (−0.61, 58.3) 8.2 (−43.8, 60.2)
P-value (groups) < 0.001; P-value (time) = 0.001; P-Value (interaction) < 0.001
Glucose(mmol/l)
Baseline 5.3 ± 1.0 10.0 ± 1.1 7.1 ± 1.3 10.8 ± 1.2 12.4 ± 1.2 10.2 ± 1.0 9.4 ± 1.2 9.1 ± 1.0
6 months 5.7 ± 1.1 9.0 ± 1.0 7.7 ± 1.3 10.3 ± 1.1 10.2 ± 1.1 10.2 ± 1.0 9.1 ± 1.1 9.7 ± 1.0
12 months 5.8 ± 1.1 8.3 ± 1.0 8.2 ± 1.2 9.9 ± 1.0 10.6 ± 1.0 11.2 ± 1.1 9.6 ± 1.2 10.1 ± 1.1
% Change at 6 months C 9.3 (−11.9, 30.6) −10.5 (−35.1, 14.0) 8.6 (−50.2, 67.5) 1.7 (−29.2, 25.7) −19.6 (−69.4, 30.0) 0.8 (−17.4, 19.2) −2.7 (−35.1, 29.6) 7.0 (−17.3, 31.6)
% Change at 12 months C 9.4 (−12.3, 31.2) −18.2 (−52.8, 16.2) 12.6 (−65.1, 90.7) −6.7 (−36.3, 22.7) −15.6 (−79.6, 48.2) 9.7 (−11.2, 31.1) 2.5 (−36.9, 41.9) 10.5 (−19.7, 40.9)
P-value (groups) < 0.001; P-value (time) = 0.51; P-Value (interaction) = 0.26
Data represented by Mean ± standard error; C Percent changes represent the absolute difference from baseline in the log-transformed data multiplied by 100; b p ≤ 0.001; a p ≤ 0.01; ‘*’ Represents significant difference
from the baseline. Level of significance is at p ≤ 0.05.
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Table 2 Male and female group comparisons of blood pressure and total cholesterol at different time points
Systolic BP(mmHg) Control Rosiglitazone Diet Insulin Insulin + Orals Metformin Oral agents combination Sulphonylurea
Male
N 72 48 4 30 6 65 16 26
Baseline 119.1 ± 1.0 129.4 ± 1.0 114.4 ± 1.0 127.1 ± 1.0 139.1 ± 1.1 123.9 ± 1.0 139.3 ± 1.1 123.9 ± 1.0
6 months 131.3 ± 1.0 131.3 ± 1.0 134.0 ± 1.2 125.0 ± 1.0 138.4 ± 1.0 124.1 ± 1.0 132.6 ± 1.0 126.2 ± 1.0
12 months 130.7 ± 1.0 130.6 ± 1.1 - 130.7 ± 1.1 124.0 ± 1.0* 126.2 ± 1.0 133.2 ± 1.1* 128.3 ± 1.0
Female
N 79 1 11 25 6 56 21 31
Baseline 114.0 ± 1.2 139.7 ± 1.0 127.9 ± 1.1 127.6 ± 1.0 121.4 ± 1.0 128.7 ± 1.1 130.4 ± 1.1 127.5 ± 1.0
6 months 115.9 ± 1.1 - 124.6 ± 1.1 122.9 ± 1.0 126.8 ± 1.0 126.2 ± 1.0 124.3 ± 1.0 132.1 ± 1.0
12 months 116.4 ± 1.0 - 132.7 ± 1.0 125.1 ± 1.1 129.1 ± 1.1 129.2 ± 1.0 124.3 ± 1.0* 126.6 ± 1.0
Diastolic BP(mmHg)
Male
Baseline 75.4 ± 1.0 71.8 ± 1.0 72.2 ± 1.0 77.2 ± 1.0 74.5 ± 1.0 80.0 ± 1.0 74.0 ± 1.0 80.0 ± 1.0
6 months 74.4 ± 1.0 80.6 ± 1.1 72.4 ± 1.0 79.0 ± 1.1 80.1 ± 1.1 78.2 ± 1.0 83.0 ± 1.1 83.5 ± 1.1
12 months 74.1 ± 1.0 83.8 ± 1.1* - 80.7 ± 1.1 87.5 ± 1.1* 76.4 ± 1.0 87.4 ± 1.1* 85.6 ± 1.1
Female
Baseline 74.0 ± 1.0 89.9 ± 1.1 80.4 ± 1.1 80.7 ± 1.1 76.5 ± 1.0 81.2 ± 1.0 80.6 ± 1.0 79.1 ± 1.0
6 months 72.4 ± 1.0 - 74.2 ± 1.0 76.8 ± 1.0 79.7 ± 1.0 78.2 ± 1.0 82.2 ± 1.0 72.5 ± 1.0
12 months 72.2 ± 1.0 - 74.7 ± 1.0 77.4 ± 1.0 77.9 ± 1.0 81.4 ± 1.0 77.3 ± 1.0 78.5 ± 1.0
Total cholesterol (mmol/l)
Male
Baseline 4.4 ± 0.02 4.7 ± 0.02 5.3 ± 0.08 4.9 ± 0.03 5.2 ± 0.06 5.3 ± 0.02 4.7 ± 0.04 5.3 ± 0.03
6 months 4.6 ± 0.02 4.4 ± 0.02 7.2 ± 0.22 5.3 ± 0.04 5.0 ± 0.06 5.1 ± 0.03 4.5 ± 0.05 4.9 ± 0.04
12 months 4.6 ± 0.03 4.0 ± 0.04 8.0 ± 0.22 4.6 ± 0.05 4.4 ± 0.12* 4.9 ± 0.03 4.3 ± 0.08 5.0 ± 0.06
Female
Baseline 4.7 ± 0.02 4.6 ± 0.15 5.3 ± 0.04 5.3 ± 0.04 5.5 ± 0.06 5.2 ± 0.02 5.2 ± 0.03 5.3 ± 0.03
6 months 4.7 ± 0.04 - 5.1 ± 0.06 4.7 ± 0.04 5.1 ± 0.07 5.3 ± 0.02 5.2 ± 0.04 5.4 ± 0.03
12 months 4.7 ± 0.03 - 5.4 ± 0.10 4.4 ± 0.04* 4.4 ± 0.07* 4.9 ± 0.03 4.7 ± 0.05 5.3 ± 0.04
Data represented by Mean ± standard error; ‘*’ Represents significant difference from the baseline. Level of significance is at p ≤ 0.05.
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Figure 1 Circulating 25-Hydroxyvitamin D Levels in A. DMT2 Males and Females and B. Non-DMT2 Control Males and Females.
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We have already demonstrated from previous cross-
sectional observations that non-diabetic adults are more
vitamin D deficient than DMT2 adults, probably because
of improved diet and multi-vitamin supplementation
[10]. We have also shown that vitamin D supplementa-
tion even up to 18 months is not sufficient to fully cor-
rect vitamin D status, but nevertheless confers
improvement in the metabolic profiles among the
DMT2 adults, including insulin sensitivity [7]. The sig-
nificant improvements in the metabolic status of DMT2
subjects secondary to vitamin D supplementation have
also been documented in other interventional and clin-
ical trial studies with respect to glucose homeostasis, al-
though beneficial effects in vascular function fell short
[11,12]. A recent review by Pilz and colleagues observed
that the modest effects of vitamin D on glycemic control
and insulin resistance in a few randomized controlled
trials are insufficient to recommend vitamin Dsupplementation for DMT2 patients [13]. The present
interventional study highlighted how the different anti-
diabetic therapies influence/interfere with circulating
levels of 25-OHVitD before and after 12-months of vita-
min D supplementation, and shed light as to how these
anti-DM therapies inhibit/activate the beneficial effects
of such intervention.
In the rosiglitazone group, vitamin D supplementation
increased the mean circulating 25-OHVitD level of all sub-
jects and had favorable effects on the circulating triglycer-
ides, which was observed only in males. Current evidence
states that rosiglitazone is not superior to other anti-
diabetic drugs, such as metformin, when it comes to im-
proving lipid profile [14]. Nevertheless, rosiglitazone affects
vitamin D status by selective agonism of peroxisome
proliferator activated receptors (PPAR-gamma), which are
present in muscle, liver and adipose tissue [15]. It is prob-
ably through the agonist effect of rosiglitazone on circulat-
ing 25-OHVitD levels that indirectly contributed to the
Table 3 Male and female group comparisons of hdl-cholesterol, triglycerides and vitamin d at different time points
HDL(mmol/l) Control Rosiglitazone Diet Insulin Insulin + Orals Metformin Oral agents combination Sulphonylurea
Male
Baseline 0.57 ± 0.05 0.94 ± 0.06 0.99 ± 0.22 0.94 ± 0.08 0.81 ± 0.18 0.92 ± 0.06 0.93 ± 0.11 0.92 ± 0.09
6 months 0.92 ± 0.09* 1.0 ± 0.17 - 1.0 ± 0.17 0.86 ± 0.26 0.81 ± 0.13 1.1 ± 0.26 1.0 ± 0.17
12 months 0.94 ± 0.15* 0.97 ± 0.13 - 0.88 ± 0.12 1.1 ± 0.32* 0.72 ± 0.19 0.88 ± 0.30 0.98 ± 0.28
Female
Baseline 0.76 ± 0.03 0.88 ± 0.22 1.1 ± 0.07 1.1 ± 0.04 1.0 ± 0.09 0.96 ± 0.03 1.0 ± 0.05 0.99 ± 0.04
6 months 1.0 ± 0.06* - 1.0 ± 0.16 1.0 ± 0.13 1.0 ± 0.15 1.0 ± 0.05 1.2 ± 0.13 1.0 ± 0.07
12 months 0.99 ± 0.06* - 1.2 ± 0.08 1.0 ± 0.17 1.1 ± 0.07 1.1 ± 0.10 1.1 ± 0.09
Triglycerides (mmol/l)
Male
Baseline 1.3 ± 0.03 2.3 ± 0.04 1.6 ± 0.16 1.7 ± 0.06 2.7 ± 0.13 2.1 ± 0.04 2.3 ± 0.08 2.2 ± 0.06
6 months 1.2 ± 0.06 1.5 ± 0.04* 1.1 ± 0.21 1.9 ± 0.09 1.7 ± 0.13* 2.4 ± 0.07 1.6 ± 0.09* 1.8 ± 0.07
12 months 1.4 ± 0.07 1.5 ± 0.07* 1.3 ± 0.22 1.7 ± 0.10 2.2 ± 0.12 2.3 ± 0.07 1.5 ± 0.12* 2.0 ± 0.11
Female
Baseline 1.2 ± 0.03 2.5 ± 0.28 1.6 ± 0.08 1.9 ± 0.05 2.1 ± 0.11 1.7 ± 0.04 1.8 ± 0.06 1.9 ± 0.05
6 months 1.3 ± 0.08 - 1.5 ± 0.12 1.8 ± 0.07 2.1 ± 0.13 1.8 ± 0.05 1.9 ± 0.09 2.2 ± 0.06
12 months 1.2 ± 0.06 - 1.8 ± 0.20 1.3 ± 0.08 1.7 ± 0.13* 1.6 ± 0.06 1.6 ± 0.10 2.0 ± 0.07
Vitamin D (nmol/l)
Male
Baseline 21.6 ± 1.0 33.7 ± 1.0 25.3 ± 1.0 34.9 ± 1.0 35.1 ± 1.0 35.7 ± 1.0 34.5 ± 1.0 34.5 ± 1.0
6 months 30.8 ± 1.0* 48.4 ± 1.0* 39.1 ± 1.1* 57.6 ± 1.1* 52.8 ± 1.2* 60.6 ± 1.1* 49.6 ± 1.1* 49.6 ± 1.1*
12 months 30.2 ± 1.1* 50.4 ± 1.1* 23.1 ± 1.0 50.1 ± 1.1* 45.8 ± 1.1* 54.5 ± 1.0* 53.7 ± 1.0* 53.1 ± .1.1*
Female
Baseline 17.6 ± 1.0 19.2 ± 1.0 24.0 ± 1.0 29.6 ± 1.0 33.2 ± 1.0 34.7 ± 1.0 34.6 ± 1.1 40.4 ± 1.0
6 months 24.2 ± 1.0 - 33.3 ± 1.1 53.5 ± 1.1* 59.1 ± 1.0* 66.0 ± 1.2* 42.1 ± 1.2* 54.5 ± 1.1*
12 months 22.6 ± 1.0 - 29.2 ± 1.0 45.4 ± 1.1* 49.1 ± 1.0* 57.9 ± 1.1* 42.9 ± 1.2* 46.8 ± 1.0*
Data represented by Mean ± standard error; ‘*’ Represents significant difference from the baseline. Level of significance is at p ≤ 0.05.
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group since no information was available in females.
In the insulin alone group, significant improvement
was observed in the mean total cholesterol of females,
while other metabolic parameters remained unchanged.
The finding is in accordance with a recent clinical trial
done in females with polycystic ovary syndrome (PCOS),
who also benefitted from vitamin D3 supplementation in
terms of decreased cholesterol levels [16]. However, the
improvement in the cholesterol levels secondary to vita-
min D correction were not observed in other trials in-
volving the general population in both the short- and
long term [17,18].
In contrast, the insulin + oral agents group showed
more significant improvements in the metabolic profile,
which included triglycerides and total cholesterol, as well
as systolic blood pressure and HDL-cholesterol in the
males. Vitamin D correction may protect against in-
creased cardiovascular risk through the promotion oflarge HDL particle formation, which increases reverse
cholesterol transport [15]. These large HDL-cholesterol
particles may form because of stimulation of apolipopro-
tein A1, the largest component of HDL-cholesterol, by
vitamin D [19]. While the mechanism of why this effect
was only apparent in the insulin + oral agents group
cannot be addressed in the present study, it is worthy to
mention that vitamin D correction under this particular
regimen was more beneficial in terms of improving
cardiometabolic profile than the standard DMT2
treatments.
No significant changes were seen in other groups (met-
formin, oral agent-combinations and sulphonylurea) in re-
lation to vitamin D supplementation, with the exception of
increased levels of 25-OHVitD. Of note is the lack of a sig-
nificant increase in the HDL-cholesterol levels of the
sulphonylurea group, which can be clinically favorable,
since DM patients on sulphonylureas had a lower HDL-
cholesterol than DMT2 patients on insulin and diet, not to
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lipid profile, making it a positive risk factor for ischemic
heart disease in patients with DMT2 [20-23]. It is also clin-
ically favorable in the sense that most probably the vitamin
D supplementation is sufficient to counteract the HDL-
lowering ability of sulphonylureas, but not sufficient in
increasing HDL-levels, making the final level similar to
previous measurements. Furthermore, the increased 25-
OHVitD levels in the metformin group with no added
metabolic improvements may imply, at least, that metfor-
min does not affect negatively vitamin D correction in
these patients [24].
The authors acknowledge several limitations. The
small sample size of some DMT2 groups may have cre-
ated bias and thus results from these groups should be
interpreted with caution. Other confounders, such as
diet and physical activity, were not accounted for in the
study. Furthermore the mean doses of medications were
not documented and therefore the dose dependent effect
cannot be verified. Nevertheless, this is one of the first
studies to compare how different DMT2 therapies affect
vitamin D supplementation. While all groups seemed to
increase their levels of 25-OHVitD after onset supple-
mentation, it appears that those DMT2 patients on insu-
lin in combination with other drugs was the group that
benefitted the most as compared with other groups in
terms of improving cardiovascular risk. Further studies
on the effects of vitamin D supplementation in harder
outcomes such as HOMA β-function in these groups
should be considered.
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